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Summary The objective was to investigate how prostate cancer and its treatment affects sexual, urinary and
bowel functions and to what extent eventual complications cause distress. A questionnaire was sent to 431 men
aged 50-80 years with prostate cancer diagnosed in 1992 in the Stockholm area (Sweden) and 435 randomly
selected men with a similar age distribution. Sexual function, as compared with their youth, was diminished in
a majority of all men. The prostate cancer patients were, however, more likely to report low frequency and/or
intensity in all aspects of sexual function. A majority of the men were distressed by a waning sexual capacity.
The proportion of men with prostate cancer who were severely distressed owing to a decline in sexual function
was larger than in the reference group. The willingness to trade off an intact sexual function for long-term
survival varied considerably among the men in the reference group. Urinary and bowel symptoms were less
common than a waning sexual function in both groups, and few appeared to be severely distressed by urinary
or bowel symptoms. A decline in sexual functions was the most common cause of disease-specific distress in
men with prostate cancer.
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Several studies have indicated that disease-specific impair-
ments and treatment-specific side-effects in prostate cancer
patients involve mainly urinary and bowel symptoms and
decreased sexual function (Schover, 1993). In a previous
retrospective study of men with localised prostate cancer who
had undergone external beam radiation therapy we found a
significant decrease in all aspects of the sexual function after
treatment. Moreover, a majority of the men who experienced
a diminished sexual function were also distressed by this
(Helgason et al., 1995). Other existing data have indicated
that distress due to sexual and/or urinary and bowel
symptoms may be common among prostrate cancer patients
(Berger et al., 1993; Pedersen et al., 1993; Brasilis et al., 1995;
Litwin et al., 1995).
An attempt to investigate the willingness of a non-prostate
cancer population, in the same age group as prostate cancer
patients, to trade off life expectancy for an intact sexual
function indicated that a majority of men were willing to do
this (Singer et al., 1991). However, the number of men
surveyed was small and the study was not population based,
precluding a generalisation to the general population.
The primary aim of the present study was to identify and
quantify the most important disease-specific distress for
prostate cancer patients. We also wanted to measure the
prevalence of the relevant symptoms in a reference
population without prostate cancer and assess the will-
ingness to trade off long-term survival for an intact sexual
function.
Materials and methods
In October 1993, we identified all 450 men who were alive
and had been diagnosed with prostate cancer in 1992 in the
area of Stockholm, Sweden, and who were 50-80 years of
age at the time. An equal number of men were randomly
selected from the same geographical region to gain reference
data. The reference group was frequency matched to have a
similar age distribution as men with newly detected prostate
cancer. The random selection was possible as all Swedish
citizens have an individual civic registration number and are
included in a population registry. We excluded all men not
born in Sweden or dead at time of identification, leaving 431
patients and 435 men in the reference group. The study was
approved by the regional ethics committee.
After a letter of introduction, the men in both groups were
sent a questionnaire including 'The Radiumhemmets Scale of
Sexual Function' and questions assessing urinary and bowel
functions. Questions concerning concurrent disease and
prescribed medication were also incorporated. The prostate
cancer patients were asked which treatment or treatments
they had been subjected to for their prostate cancer. The
questionnaire was confidential and the men indicated that
they had returned it on an identification form that was
returned separately from the completed questionnaire. Men
not returning the identification form were reminded first by
letter and then by a telephone call. If possible, those still not
responding were contacted by telephone to assess the reason
for non-response. Data collection started in October 1993
and ended in April 1994.
'The Radiumhemmets Scale of Sexual Function' has
previously been developed through successive in-depth
interviews with 30 prostate cancer patients (Helgason et al.,
1995). The questionnaire evaluates frequency and/or intensity
of three aspects of sexual function: sexual desire, erectile
capacity and orgasm/ejaculation. The questionnaire also
assesses if and to what extent a change in these functions
distresses the men. Frequency of sexual functions and distress
related to functional changes are evaluated by questions with
five optional answers ranging from high to low level of
function or distress. Erection stiffness including morning
erections, spontaneous erections and sexually stimulated
erections is assessed on an eight-category scale. Erection
stiffness 'usually sufficient for intercourse' in at least one of
the three erection stiffness domains was defined as
'physiological potency'.
A module was developed for the present study to assess
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urinary and bowel symptoms and the related distress. The
module assesses symptoms and distress on a four-grade scale.
The symptoms assessed include urinary leakage, urinary
urgency, weak urinary stream, fecal leakage, bowel urgency
and constipation.
A question designed to assess the willingness to trade off
long-term survival, given they had a potentially deadly
disease, against preserving the present level of sexual
function was included in the questionnaire to all men in the
reference group. The question was constructed to reflect the
situation regarding localised prostate cancer: 'Assume that
you have a disease that may be life-threatening but 80% of
the patients are still alive after 10 years. It is unclear if the
available treatment prolongs the patient's life. One treatment
side-effect is a decrease in sexual function in a majority of the
patients. Approximately 50% of patients who are potent
before treatment will become impotent after the treatment.
Would you in that situation accept the treatment or not?' On
ethical grounds it was decided not to include this question in
the questionnaire to all patients as we did not know how the
patients would react to this line of questioning. However, as
a pilot study the question was sent to 25 randomly selected
men with prostate cancer.
To assess the representativeness of the reference group, the
prevalence of diabetes mellitus and myocardial infarction was
compared with available official statistics for the prevalence
of these two conditions in Swedish men (Statistics, Sweden,
1996), using indirect age standardisation. Information
regarding the prevalence of prostate cancer in 50 to 80-
year-old men in the Stockholm region, was retrieved from the
local cancer registry. A ratio of proportions was calculated
with a 95% confidence interval based on the method
proposed by Mantel and Haenszel (Rothman, 1986). For a
comparison between two proportions, a P-value was
calculated using Fisher's exact test (Rothman, 1986). A
two-sided P-value below 0.05 was considered statistically
significant.
Results
The questionnaire was returned by 73% of men in the
reference group and 79% of the prostrate cancer patients
(Table I). Reasons for non-response are presented in Table I.
Five men in the randomly selected group reported that they
had prostate cancer and were excluded from further analysis,
leaving 314 men in the reference group. The median age of
responding men with and without prostate cancer was 72
years (range 51-80 years) and 68 years (range 50-80 years)
respectively (Table II). Of the men with prostate cancer, 109
had received endocrine treatment, 22 had been subjected to
radical prostatectomy only, 37 had been irradiated only, 35
reported endocrine treatment subsequent to radical surgery
or radiotherapy and 139 men had not received any of these
treatments at the time of investigation.
Compared with the reference group, a larger proportion of
the prostate cancer patients reported low frequency of sexual
functions (less than once a month) in all aspects of sexuality
assessed in this study, the ratio of proportions (with 95%
confidence interval) being 2.0 (1.6-2.4) for sexual desires, 2.3
(1.9-2.8) for sexually stimulated erections, 1.6 (1.4-1.8) for
intercourse and 2.1 (1.8-2.5) for orgasm. All differences
between the groups were statistically significant (P<0.05)
(not in table). Any decrease in sexual function as compared
with youth is presented in Table III.
A majority of the men in both groups reported they were
troubled by a diminished sexual function compared with
youth (Table IV), and many stated that this distressed them
severely (Figure 1). There was no significant difference
between the prostate cancer patients and the reference group
with regard to the proportion of men reporting distress due
to waning sexual function when all degrees of distress were
taken into account. The prostate cancer patients were,
however, significantly more likely to be distressed (the
highest category on a five-category ordinal scale) because of
a waning sexual function (P<0.05) with a ratio of
proportions (with 95% confidence interval) of 1.5 (1.1-2.2)
for sexual desire, 1.3 (1.0-1.6) for erection capacity, 1.5
(1.2-1.9) for orgasm pleasure and 2.1 (1.4-3.0) for ejaculate
volume (not in table).
Compared with men in the reference group, men with
prostate cancer reported a significantly higher incidence of
'physiological impotence' (P<0.001) with a ratio of propor-
tions (with 95% confidence interval) of 2.3 (1.9-2.7). There
was no statistically significant difference between the
'physiologically impotent' men in the prostate cancer group
vs the reference group with regards to the extent to which they
were distressed by their erectile dysfunction. The relative risk
being 0.9(0.8-1.2). (not in table).
Of the men in the reference group, 299 answered the
question regarding the willingness to trade off the possibility
of longer life expectancy for an intact sexual function if the
curative effect of available treatment was uncertain (Table V).
Of these men, 62% stated they were willing to make this
trade-off. Moreover, 19% were not willing to risk their sexual
function even if it was proven that the treatment prolonged
life, given that they had 80% chance of being alive after 10
years without any curative treatment. On the other hand,
38% of the men in the reference group would choose
treatment irrespective of eventual effects on their sexual
function. There was no difference in the willingness, or
unwillingness, for a trade-off in various age groups (Table V).
Of the 25 men with prostate cancer included in the pilot
study, 22 answered the question and 63% stated that they
were willing to trade off the possibility of longer life for an
intact sexual function (not in table).
Table I Response rate and reasons for not responding to the questionnaire (prostate
cancer patients compared with the reference group)
Reference Prostate cancer
group group
(n = 435) (n = 431)
Answering the questionnaire: 319 (73%)a 342 (79%)
Reasons for non-response
Not interested in participatingb 38 (8%) 19 (4%)
Physical disabilitiesc 14 (3%) 24 (6%)
Too occupied to participate 14 (3%) 15 (3%)
Could not be locatedd 17 (4%) 6 (1%)
Unreachable by telephonee 38 (9%) 25 (6%)
aFive men in the reference group reported that they had prostate cancer and were
excluded from further analysis, leaving 314 men in the reference group. bMen stating, for
example, that they never partake in surveys or that they did not like the context of the
questions. cIncluding blindness, mental retardation, senility, men 'too sick to participate'
etc. dLiving abroad or not living at registered address. 'No registered telephone number,
no answer, phone closed.Disease and treatment-related distress in men with prostate cancer
AR Helagson et al
Table II Characteristics of men without and with prostate cancer when answering the questionnaire
Men with various treatmentsfor prostate cancer
Men without Men with Endocrine
prostate prostate treatmentl Radical External Mixed Other
cancer cancer castration prostatectomy radiation groupa casesb
(n = 314) (n =342) (n = 109) (n = 22) (n = 37) (n = 35) (n = 139)
Median age (years) 68 72 73 69 69 67 73
Age range (years) 50-80 51 -80 54-79 54-79 55-78 51-79 57-80
Number of men reportingc 178 (57%) 181 (53%) 49 (73%) 16 (73%) 23 (60%) 21 (60%) 70 (52%)
no concurrent disease
Number of men reportingd 180 (57%) 152 (44%) 40 (37%) 11 (50%) 18 (49%) 12 (34%) 71 (51%)
no prescribed medication
aRadical prostatectomy or external beam radiation therapy, followed by hormonal manipulation. bPatients receiving no initial treatment.
cReporting no history of following diseases that may affect sexual functioning; psychiatric disorders, diabetes mellitus, hyperthyroidism,
intermittent claudication, hypertensive disease, myocardial infarction, Parkinson's disease, epilepsy, renal disorders, obstructive bronchial disease.
dReporting not to have taken any prescribed medication during the last 12 months.
Table Im Proportiona of all men reporting any degree of decrease in sexual function as compared with their youth and/or any degree of
urinary/bowel complications
Men with various treatmentsfor prostate cancer
Men without Men with Endocrine
prostate prostate treatmentl Radical External Mixed Other
Aspects cancer cancer castration prostatectomy radiation group cases
assessed (n = 314) (n = 342) (n = 109) (n = 22) (n = 37) (n = 35) (n = 139)
Sexual desires/thoughts 156/305 (51%) 240/321 (75%) 82/99 (83%) 16/22 (73%) 27/37 (73%) 24/33 (73%) 91/130 (70%)
Erection capacity 235/304 (77%) 286/318 (90%) 93/97 (96%) 19/22 (86%) 35/37 (95%) 34/34 (100%) 105/128 (82%)
Orgasm pleasure 209/305 (71%) 252/302 (83%) 81/93 (87%) 14/20 (70%) 32/37 (86%) 26/31 (84%) 99/121 (82%)
Ejaculate volume 232/298 (78%) 256/287 (89%) 78/89 (87%) 18/21 (86%) 31/33 (94%) 25/28 (89%) 104/116 (90%)
Urine leakage 42/291 (14%) 93/313 (30%) 24/100 (24%) 13/20 (65%) 12/36 (33%) 7/35 (20%) 37/122 (30%)
Urinary urgency 39/283 (14%) 94/312 (30%) 29/100 (29%) 3/20 (15%) 9/36 (25%) 11/35 (31%) 42/121 (35%)
Weak urine stream 124/286 (43%) 165/321 (51%) 60/104 (58%) 8/21 (38%) 15/37 (41%) 21/35 (60%) 61/124 (49%)
Faecal leakage 13/292 (4%) 27/321 (8%) 10/104 (10%) 2/22 (9%) 5/36 (14%) 4/35 (11%) 6/124 (5%)
Bowel urgency 27/280 (10%) 68/309 (22%) 20/99 (20%) 2/20 (10%) 13/37 (35%) 11/34 (32%) 22/119 (18%)
Constipation 27/290 (9%) 63/317 (20%) 21/104 (20%) 4/21 (19%) 5/37 (14%) 12/35 (34%) 21/120 (18%)
aVariations in denominators of'n' are caused by different response rates for individual questions in the questionnaire.
Table IV Proportion' of men reporting that they were distressed because of decreased sexual function (as compared with their youth) and/or
any degree of urinary/bowel complications
Men with various treatmentsfor prostate cancer
Men without Men with Endocrine
prostate prostate treatment/ Radical External Mixed Other
Aspects cancer cancer castration prostatectomy radiation group cases
assessed (n = 314) (n = 342) (n = 109) (n = 22) (n = 37) (n = 35) (n = 139)
Sexual desires/thoughts 118/305 (39%) 184/321 (57%) 59/99 (60%) 15/22 (68%) 20/37 (54%) 17/33 (52%) 73/130 (56%)
Erection capacity 192/304 (63%) 220/318 (69%) 61/97 (63%) 18/22 (82%) 30/37 (81%) 25/34 (74%) 86/128 (67%)
Orgasm pleasure 171/305 (56%) 201/302 (67%) 55/93 (59%) 13/20 (65%) 27/37 (73%) 22/31 (71%) 84/121 (69%)
Ejaculate volume 141/298 (47%) 168/287 (59%) 46/89 (52%) 15/21 (71%) 26/33 (79%) 15/28 (54%) 66/116 (57%)
Urine leakage 10/291 (3%) 45/313 (14%) 12/100 (12%) 6/20 (30%) 7/36 (19%) 5/35 (14%) 15/122 (12%)
Urinary urgency 26/283 (9%) 67/312 (21%) 23/100 (23%) 2/20 (10%) 7/36 (19%) 10/35 (29%) 25/121 (21%)
Weak urine stream 17/286 (6%) 50/321 (16%) 20/104 (19%) 1/21 (5%) 2/37 (5%) 9/35 (26%) 18/124 (15%)
Faecal leakage 6/292 (2%) 12/321 (4%) 6/104 (6%) 0/22 (0%) 2/36 (6%) 2/35 (6%) 2/124 (2%)
Bowel urgency 8/280 (3%) 37/309 (12%) 10/99 (10%) 0/20 (0%) 6/37 (16%) 9/34 (26%) 12/119 (10%)
Constipation 8/290 (3%) 25/317 (8%) 10/104 (10%) 1/21 (5%) 1/37 (3%) 6/35 (17%) 7/120 (6%)
aVariations in denominators of 'n' are caused by different response rates for individual questions in the questionnaire.
Urinary and bowel symptoms were less common than a
decline in sexual function in both the men with and without
prostate cancer (Table III). Among the urinary and bowel
symptoms, a weak urinary stream was most common in both
groups (Table III) but few men were troubled by it (Table IV
and Figure 2). Of the urinary and bowel symptoms, distress
due to urinary urgency was the most frequent in both groups
(Table IV and Figure 2). Of the men subjected to radical
surgery, many reported a urinary leakage (Table III) and
one-third appeared to be troubled by this (Table IV) but only
4% of the men reporting urinary leakage stated that they
were severely distressed (not in Table). Of all men, few stated
that they were severely distressed by urinary or bowel
symptoms (Figure 2).
Of those reporting any complication, the prostate cancer
patients reporting urinary leakage, weak urinary stream and
bowel urgency were significantly more likely to be distressed
by this than were the men in the reference group reporting
similar symptoms, the ratio of proportions (with 95%
confidence interval) being 2.0 (1.1-3.6), 2.2 (1.3-3.6) and
1.8 (1.0-3.4) (not in Table). There was no significant
difference between the groups with regard to distress causedDisease and treatment-related distress in men with prostate cancer
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Figure 1 Number and per cent of all men stating that they were
severely distressed by a decrease in various aspects of sexual
function. Severe distress refers to the highest category on a five-
category ordinal scale. E. Men without prostate cancer; *. men
with prostate cancer.
_ n=9
n2 -5 3% n2 n 3 n = 3 n= 2 nE= 1 1% 1% n=O n=1n=0 1% n=1 1%
0%_ - _ _ °% °%lI °% _
Urine Urinary
leakage urgency
Weak Faecal Bowel Constipation
urine leakage urgency
stream
Figure 2 Number and per cent of all men stating that they were
seri,erelyi distressed by various urinary/bowel complications. Severe
distress refers to the highest category on a four-category ordinal
scale. E. Men without prostate cancer; *, men with prostate
cancer.
Table V Proportion of randomly selected men aged 50-80 stating their willingness to trade off the
possibility of longer life expectancy against preserving their present level of sexual function (see
question in Materials and methods section)
All ages
50 -80
Age
5)-59
Age
60 69
Age
70 80
Would not accept
treatment
Would accept treatment
only if it prolonged life
10 years or more
3 10 years
1- 2 years
Accept treatment
unconditionally
56 299 (19%) 10 60 (17%) 18 108 (17%) 28/ 129 (22%)
83 299 (28%)
36,299 (12°O)
11,299 (4%)
19 60 (32%)
4,60 (7%)
0 60 (0%)
35
10
6
108 (32°O)
108 (9%)
108 (6%)
29 129 (22%)
22 129 (17%)
5 129 (4%)
113 299 (38%) 27,60 (45%) 39 108 (36%) 45 129 (35%)
by other urinary or bowel symptoms. In an overall
assessment of the effects of urinary and bowel symptoms,
the proportion of all men reporting severe distress due to
symptoms in one or more aspect of these functions was 4%
(14/342) for the prostate cancer patients and 2% (6/314) for
the men in the reference group (not in Table).
The prevalence of prostate cancer, diabetes mellitus and
myocardial infarction was 2e, 6% and 11% in the reference
group and 2%, 5% and 13% in the general population.
Discussion
In the present study a decline in sexual desire, erectile and
orgasm functions was the most common disease-specific
distress in an unselected prostate cancer population. Sexual
function as compared with their youth was diminshed in the
majority of men in the investigated age group both with and
without prostate cancer. The prevalence and severity of
sexual dysfunction was significantly greater in the prostate
cancer population. There was a large variation in the
willingness to trade off increased survival for an intact
sexual function, emphasising the need to tailor treatment
decisions for each individual patient. Urinary and bowel
symptoms were less prevalent than a waning sexual function
and few men appeared to be severely distressed by them.
A decline in one or more aspects of sexual function was
apparent in the majority of the investigated men. The
prostate cancer patients were more likely to report a low
frequency and intensity of erections compared with the men
in the reference group. These findings were consistent with
those of others (Schover, 1993; Litwin et al., 1995). A waning
sexual function distressed the majority of men with and
without prostate cancer. For the men with prostate cancer
our findings were corresponding to the previously published
data (Pedersen et al., 1993; Brasilis et al., 1995; Helgason et
al., 1995; Litwin ct al., 1995).
The men were clearly discrepant in valuing their sexual
function with approximately one-fifth not willing to risk their
sexual function for any improvement in life expectancy, and
another two-fifths not willing to trade off any possibility of a
prolonged life for a preserved sexual function. This individual
difference in willingness to risk the possibility of a longer life
expectancy for an intact sexual function emphasises the
heterogeneity in how men value their sexual function.
However, a majority of the men stated they were willing to
trade off life expectancy for an intact sexual function. In this
respect our data for the men without prostate cancer
correspond with the findings of Singer et al. (1991). The
proportion of men with prostate cancer willing to do a trade-
off was similar to the reference group but a comparison
between the groups would be imprecise owing to a low
number of surveyed patients with prostate cancer. Such data
from men with prostate cancer has to our knowledge not
been presented before.
The prevalence of urinary and bowel symptoms among the
men with prostate cancer by and large correspond to data
previously published (Perez et al., 1986; Fowler et al., 1993;
Jonler et al., 1995). However, few men in the present study
appeared to be severely distressed by urinary and bowel
symptoms. Of the investigated urinary symptoms, leakage
was the most common cause of severe distress in both men
with and without prostate cancer. Severe distress because of
bowel symptoms was reported by only 1% of the patients
and no men in the reference group. Of the men reporting any
degree of urinary or bowel symptoms, the prostate cancer
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patients were significantly more likely to be severely
distressed by urinary leakage, weak stream and bowel
urgency.
Changes in sexual function. and to some extent unrnary
and bowel symptoms, reported by the men with prostate
cancer, varied with the different treatments. However, a
comparison of the various treatment groups was not the
primary aim of the present study and comparisons are
difficult to make as the patients were selected on clinical
grounds to different treatments. For example, patients
receiving endocrine therapy most likely had metastatic,
locally advanced and/or poorly differentiated tumours.
Patients subjected to radical surgery or radiotherapy only
presumably had a clinically localised tumour. Men who had
received endocrine therapy subsequent to radical surgery or
radiotherapy most likely had tumours that had progressed
after the initial treatment or had adverse prognostic findings
at treatment. Those given no initial treatment probably had
low-grade, clinically localised disease and were also older
than the patients treated with curative intent. The initially
untreated group may also have included some patients with
metastatic or advanced disease without symptoms.
The response rate for the questionnaire was slightly lower
for the reference group which may be owing to the fact that
the majority of these men did not have any specific disease
affecting the investigated functions, thereby making them
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